News

Is Cannabis the Antibiotics of the 21st Century?

Is Cannabis the Antibiotics of the 21st Century?
25 July, 2021

Prof. Doron Steinberg, a researcher and lecturer from the Faculty of Dental Medicine and the Director of the Biofilm Research Lab, says that modern microbiology is not designed to kill viruses but rather to attack the biofilm construction.  In his lab, basic research is combined with clinical applications for a variety of developments and innovations to help combat biofilm as a major cause for infectious diseases like fungal diseases and Cystic Fibrosis that he is currently researching. “My goal is to think of additional applicable applications for cannabinoids, and the possibilities are endless.”

Read More

 

Prof. Steinberg says: “We’re involved with a joint study with the head of the Pulmonary Department at Hadassah Ein Kerem, Prof. Malena Cohen.  Cystic Fibrosis is a terminal illness of the biofilm of the lungs with a very rapid morbidity.  Patients are subjected to high levels of all sorts of antibiotics daily which on occasion can be the actual cause of their deaths.  Our hope is to find a cannabinoid that is more effective for the treatment of this condition.”

 

An additional research focus in the joint study, alongside measuring the effectiveness of the cannabinoids, is how they can be best delivered to the lungs.  The team has developed an innovative solution that has already been tested and shown very positive responses.  Last month the team submitted a research grant to the Cystic Fibrosis Foundation.

 

“The next stage that we are already working on, is on more ‘traditional’ infectious diseases, that will be easier to progress with in terms of regulatory issues because if we are successful when it comes to Cystic Fibrosis that these non-terminal diseases should be simpler in that regard.”

 

Prof. Steinberg’s most recent findings on cannabinoids research were published in the journal Scientific Reports.  Hebrew University is home to a Cannabinoids Research Center that is a global leader in this field and enjoys working partnerships with leading Israeli companies that are investing in new developments in this area as well as via the “Maadan” track of the Ministry of Health that has a vested interest in developing Israeli interests in science and healthcare. 

Read Less

Understanding the Impact of Medical Marijuana on Children, a Meta-Analysis / Ilan Matok

Understanding the Impact of Medical Marijuana on Children, a Meta-Analysis / Ilan Matok
6 July, 2021

In recent years, the use of medical cannabis to treat sick kids is on the rise, although questions remain about the benefits and safety of such treatments.  Now, a team of researchers from the Hebrew University of Jerusalem (HU) has completed a first-ever meta-analysis of pediatric patients treated with medical cannabis to better understand the risks and benefits of cannabis use among young patients
 

Research projects were awarded funding by the Israel Science Foundation and Scopus BioPharma Israel Ltd.

12 August, 2018

 

Congratulations to our researchers who were awarded funding by the Israel Science Foundation:

  1. Joseph Tam - Deciphering the Crosstalk between CB1 and GLUT2 in the Development of Diabetic Nephropathy
  2. Dmitry Tsvelikhovsky - Stretching the Model of TRPV1 Activation

 

Congratulations to our researchers who were awarded funding by Scopus BioPharma Israel Ltd:

Hebrew University and the city of Jerusalem to host the 'International Conference on Cannabinoids' in 2021

27 July, 2017

Jerusalem, July 26, 2017 — The International Cannabinoid Research Society (ICRS - http://icrs.co) has chosen the Hebrew University of Jerusalem to host the International Symposium on the Cannabinoids in 2021 in Jerusalem.

The ICRS is the oldest scientific society dedicated to the research in the cannabis plant, cannabinoids, and their physiological and biochemical targets. The ICRS has nearly 400 members from all over the world. The members and guests of the ICRS gather yearly to present the ICRS Symposium.